FDA panel shoots down OTC Singulair

Share this article:
FDA panel shoots down OTC Singulair
FDA panel shoots down OTC Singulair

Merck's bid to resurrect Singulair faced a setback today, as an FDA advisory panel voted 11-4 against making the drug available over-the-counter. The drugmaker had submitted Singulair as an OTC remedy for hay fever and upper respiratory allergy symptoms.

Singulair saw sales of $271 million in the first quarter of 2014, a big fall from annual sales of $3.9 billion in 2012—the year the once-daily allergy drug came off patent.

Reviewers wrote that there was “insufficient evidence to support adding the claim of 'temporarily relieves itchy and watery eyes,' for the non-prescription label.”

Another point of contention was whether Singulair's serious, albeit rare, side effects like agitation, aggression, anxiety, depression, suicidal thoughts and hallucinations could be problematic for consumers not under the supervision of a doctor—especially for patients who might use the drug off-label for asthma.

FDA panelists also cited concerns that, if approved, the drug would carry an adult-only label but may be picked up by teenagers and adolescents. “Whether the complexities of managing allergic rhinitis in the face of multiple variable treatment options can be communicated and understood by the OTC consumer will be an important issue for discussion.”

The OTC avenue has been a popular one lately among big pharma to further extend a drug's life cycle and revenue beyond its expiry. Pfizer recently started testing Lipitor for OTC use, and a non-Rx version of acid reflux drug Nexium, which Pfizer licensed from AstraZeneca, got the nod to move onto store shelves this past March.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...